Tuesday, 02 January 2024 12:17 GMT

Forge's Immuno-Oncology 360O 2027 Announces Early Keynotes And Key Topics For The Annual Meeting


Date:

(MENAFN- GlobeNewsWire - Nasdaq) BOSTON, Nov. 10, 2026 (GLOBE NEWSWIRE) -- Forge's 13th annual Immuno-Oncology 360o Summit (IO360°) will take place March 16-18, 2027, at the Hilton Park Plaza in Boston, MA.

The IO360° 2027 early keynote lineup includes:

  • Laurence Zitvogel, MD, PhD, Scientific Director, Gustave Roussy Cancer Center, on Reprogramming Cancer Immunity Through Metabolism, Nutrition and the Microbiome
  • John Pagel, MD, PhD, Senior Vice President, Clinical Development, Global Head Medical Oncology and Hematology, Eli Lilly & Co., on The Next Frontier of Cell Therapy: Clinical Progress in In Vivo Car-T for Multiple Myeloma

“IO360o provides curated content on the most pertinent scientific and clinical advances in immuno-oncology paired with business and market insights highlighting critical trends and directions of the field, in a unique blend that makes this event deeply insightful and predictive of the future of IO,” said Dr. Axel Hoos, Founder & CEO Argonaut Bio and founding advisor of IO360o.

The 2027 key topic areas include:

  • Biomarkers & Imaging
  • Business & Investing Aspects
  • Discovery/Preclinical Science
  • Translational Science
  • Cell Therapy
  • ADCs & IO
  • T-Cell Engagers
  • Cancer Vaccines
  • Multispecific Antibodies
  • Precision Immunotherapy
  • IO Combinations
  • Novel Targets

“Through 100+ multi-dimensional talks, cutting-edge presentations, future-focused panel discussions, and built-in networking, IO360o continues to deliver an environment for building impactful collaborations between trailblazers in translational science, innovators in clinical development, and pioneers in investment and business development to advance cancer treatments,” said Kate Woda, Director of IO360o.

The 2027 meeting will once again bring together top leadership in translational science and clinical development, transformational biology, investment and business development, and clinical operations from the following organizations:

  • Moderna
  • MD Anderson Cancer Center
  • Merck
  • Eli Lilly & Co
  • Kite Pharma
  • Strand Therapeutics
  • J&J Innovative Medicine
  • RA Capital
  • University of Pennsylvania
  • Immunocore
  • Morgan Stanley
  • Gustave Roussy Cancer Center

To learn more about IO360o, visit io360summit.com

About Forge
Forge is a leading global B2B events and media company, connecting buyers and sellers across high-value industries through live events, trusted media brands, digital products and year-round communities. Powered by first-party data, technology and deep market expertise, Forge helps businesses discover opportunities, build the right relationships and stay engaged well beyond the event itself. It is a company guided by a single purpose, Moving Markets.

For more information, visit forgelive.com.

Media Contact

BreAnna Bugbee
Senior Marketing Manager
Immuno-Oncology 360o Summit
...


MENAFN10112026004107003653ID1111941240


GlobeNewsWire - Nasdaq

Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.



More Story

Search